# Charles River Laboratories Announces First-Quarter 2026 Results
Canonical URL: https://biopharmsignal.com/news/CRL/charles-river-laboratories-announces-first-quarter-2026-results
Ticker: CRL
Company: Charles River
Source: Charles River
Published: 2026-05-07 11:00 EST
Original Source URL: https://ir.criver.com
## Summary

– Reports First-Quarter Revenue of $995.8 Million, GAAP Loss per Share of $(0.30), and Non-GAAP Earnings per Share of $2.06 – – Reaffirms 2026 Guidance for Organic Revenue and Non-GAAP Earnings per Share – – Repurchased $200 Million of Common Stock in First Quarter of 2026 – – Completed the

## Article Body
– Reports First-Quarter Revenue of $995.8 Million, GAAP Loss per Share of $(0.30), and Non-GAAP Earnings per Share of $2.06 – – Reaffirms 2026 Guidance for Organic Revenue and Non-GAAP Earnings per Share – – Repurchased $200 Million of Common Stock in First Quarter of 2026 – – Completed the
## Recent Company News
- 2026-06-01 12:00 EST — [Charles River Laboratories to Present at William Blair and Jefferies Conferences](https://biopharmsignal.com/news/CRL/charles-river-laboratories-to-present-at-william-blair-and-jefferies-conferences) — Source: Charles River
- 2026-05-13 12:00 EST — [Charles River Laboratories and MEDIPOST Sign Non-Exclusive MOU to Advance GMP Testing Solutions](https://biopharmsignal.com/news/CRL/charles-river-laboratories-and-medipost-sign-non-exclusive-mou-to-advance-gmp-testing-solutions) — Source: Charles River
- 2026-05-11 12:00 EST — [Charles River Accelerates Digital Pathology with AI-Powered End-to-End Workflow](https://biopharmsignal.com/news/CRL/charles-river-accelerates-digital-pathology-with-ai-powered-end-to-end-workflow) — Source: Charles River
- 2026-05-07 11:00 EST — [Charles River Laboratories Announces First-Quarter 2026 Results](https://biopharmsignal.com/news/CRL/charles-river-laboratories-announces-first-quarter-2026-results) — Source: Charles River
- 2026-04-30 12:00 EST — [Charles River Launches Rat In Vitro Fertility Services Demonstrating Embryology Capabilities](https://biopharmsignal.com/news/CRL/charles-river-launches-rat-in-vitro-fertility-services-demonstrating-embryology-capabilities) — Source: Charles River
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)